Good find @Greenwave17Been looking at some Biotech research...

Good find @Greenwave17

Been looking at some Biotech research myself in what to expect with IXHL's growth and value moving forward. Mainly looking for timeframes that will unlock value. Some key takeaways that resonate across this research into the Biotech Industry in the near term 12-18 months for investors. One key point Echoed is the high demand now generating for M & A and what Pharmaceutical Corporations are looking for;

1/ Good data, late stage drug candidates over the next 12-18 months entering late stage clinical trials.
2/ Entering late stage commercial business viability.
3/ Strong company- Quality expert management.
4/ Multiple near term pathways
5/ Good COH
6/ Revenue or near term revenue with diversification.
7/ Aggressive direction and objectives.
8/ Pathways meeting Unmet Medical Needs.

What's in store with Biotech Companies with the above attributes;
1/ Big Pharmaceutical Corporations with 6 trillion spare cash as dry powder with patent expiration/closure near term.
2/ Hundreds of Billions in patent expiration cashflow limitations.
3/ $240 billion earmarked for M & A near/short term.

With Biotech sector at an all time low not seen in many years, will opportunities in late stage development drug candidates see M & A increase in volume over the next 12-18 months.
Wonder how many of the above boxes Incannex have and will tick over the next 12-18 months.....
Have a great festive season.